Jump to content

Drilldown: Medicines

Pharmacopedia
BrowseCategoriesLog in

Choose a table:


Medicines > classes : Phenethylamine or Tryptamine or [[GLP-1 receptor agonist]] · [[Antidiabetic medicines|Antidiabetic]] · Fc-fusion biologic

Use the filters below to narrow your results.

generic:
brand:
None (51) · Nexus, Eroxan (historical, late-1980s through mid-1990s) (1) · Trulicity (1)
classes: (Click arrow to add another value)
mechanism:
5-HT2A agonist (27) · 5-HT2A agonist; 5-HT3 antagonist (1) · 5-HT2A agonist; long duration (1) · 5-HT2A agonist; MAO inhibitor (1) · 5-HT2A agonist; milder than other 2C-x (1) · 5-HT2A agonist; minor psilocybin mushroom alkaloid (1) · 5-HT2A agonist; primarily auditory effects (1) · 5-HT2A agonist; sigma-1 agonist (1) · 5-HT2A partial agonist (1) · Extremely potent 5-HT2A agonist; vasoconstrictor (1) · Extremely potent 5-HT2A agonist; very long duration (1) · Long-acting agonist of the [[GLP-1 receptor]]; Fc-fusion construct. (1) · Monoamine releasing agent; 5-HT2A agonist; MAO inhibitor (1) · Potent 5-HT2A agonist (5) · Potent 5-HT2A agonist; no oral activity (1) · Potent 5-HT2A agonist; sigma-1 agonist (1) · Potent 5-HT2A agonist; very long duration (1) · Prodrug of 4-HO-DET; 5-HT2A agonist (1) · Prodrug of 4-HO-DiPT; 5-HT2A agonist (1) · Prodrug of 4-HO-MET; 5-HT2A agonist (1) · Prodrug of 4-HO-MiPT; 5-HT2A agonist (1) · Prodrug of psilocin; 5-HT2A agonist (1) · Very potent 5-HT2A agonist; long duration (1)
uses:
None (52) · [[Type 2 diabetes mellitus]] · [[Cardiovascular risk reduction]] in T2DM (1)
starting dose:
None (52) · 0.75 mg SC weekly'"`UNIQ--ref-00000053-QINU`"' (1)
preparations:
None (52) · Pre-filled single-dose pen: 0.75 / 1.5 / 3 / 4.5 mg'"`UNIQ--ref-00000054-QINU`"' (1)
fda max:
None (52) · 4.5 mg/wk SC'"`UNIQ--ref-00000055-QINU`"' (1)
routes:
None (51) · insufflated (1) · Oral (1) · PR (1) · Subcutaneous (abdomen (1) · thigh (1) · upper arm)'"`UNIQ--ref-00000056-QINU`"' (1)
onset:
None (51) · 45-75 min (oral) (1) · Glycemic effect within days; near-maximal HbA1c effect by 4 weeks at any given dose'"`UNIQ--ref-00000057-QINU`"' (1)
duration:
None (51) · 4-8 h (1) · ~7 days (weekly dosing)'"`UNIQ--ref-00000058-QINU`"' (1)
halflife:
None (51) · Not well characterized (1) · ~5 days (~120 h)'"`UNIQ--ref-00000059-QINU`"' (1)
bioavailability:
None (51) · Not well characterized (1) · SC ~47%–65%'"`UNIQ--ref-0000005A-QINU`"' (1)
pregnancy:
None (51) · Avoid. Discontinue at least 1 month before planned pregnancy. Animal data show embryofetal harm.'"`UNIQ--ref-0000005B-QINU`"' (1) · Not established (1)
legal:
None (51) · Rx-only;'"`UNIQ--ref-0000005C-QINU`"' not a controlled substance (1) · [[USLegal:DEA Schedule I|Schedule I]] (United States) (1)

Showing below up to 53 results in range #1 to #53.

View (previous 250 | next 250) (20 | 50 | 100 | 250 | 500)


View (previous 250 | next 250) (20 | 50 | 100 | 250 | 500)

Retrieved from "https://pharmacopedia.wiki/p/Special:Drilldown/Medicines"